Planta Med 2008; 74 - PD2
DOI: 10.1055/s-0028-1084677

Structure elucidation of components with inhibitory activities of atopic dermatitis from Actinidia arguta

HM Park 1, SK Ha 1, MC Kim 1, MW Son 2, M Jin 3, HC Kwon 4, SY Kim 1, 5
  • 1Graduate School of East-West Medical Science, Kyung Hee University, #1 Seocheon-dong, Kihung-Ku, Yongin-City, Kyungki-Do, 446–701, Republic of Korea
  • 2Research Laboratory, Dong-A Pharmaceutical Company, Ltd., 47 Sanggal-dong, Kihung-ku, Yongin-City, Kyungki-Do 449–900, Republic of Korea
  • 3Lab of Pathology, College of Oriental Medicine, Daejeon University, Daejeon, 300–716, Republic of Korea
  • 4Korea Institute of Science and Technology, Gangneung Institute, 290 Daejeon-dong, Gangneung, 210–340, Republic of Korea
  • 5East-West integrated Medical Science Rearch center, Kyung Hee University, #1 Seocheon-dong, Kihung-ku, Yongin-City, Kyungki-Do 446–701, Republic of Korea

Atopic dermatitis is a common, chronic fluctuating skin disease. Over the last 30 years, prevalence of atopic dermatitis and other atopic allergic disorders has been continuously increased [1]. Therefore, the importance of research regarding the treatment of atopic dermatitis is also increasing. The fruits of Actinidia arguta (AA) were generally used as a traditional medicine for skin diseases, diuretic effect, diabetes mellitus and osteoporosis. Recently, it has been reported that AA possesses both in vivo and in vitro anti-inflammatory effects [2]. Although Actinidia arguta has high inhibitory effects on allergic diseases, the active compounds have not been identified. In this study, activity-guided isolation of the extract of the dried fruits from AA using in vitro ELISA assay for IL-4 and luciferase assay [3], led to the purification of five fatty acid compounds. The active compounds were identified as α-linolenic acid (C18:3), linoleic acid (C18:2), α-linolenic acid ethyl ester (ethyl linolenate, C18:3), linoleic acid ethyl ester (ethyl linoleate, C18:2) and stearic acid ethyl ester (ethyl stearate, C18:0), respectively. The results suggest that these five active compounds are potent inhibitors of PMA- and A23187-induced IL-4 promoter activity and IL-4 production in RBL-2H3 cells without cell toxicity.

Acknowledgements: Dong-A Pharmaceutical Company, Ltd.

References: 1. Ring, J. et al. (2001) Curr Opin Immunol 13:701–708. 2. Park, E.J. et al. (2005)J Allergy Clin Immunol 116:1151–1157. 3. Choi, J.J. et al. (2007) Arch Pharm Res 30:1102–1110.